Daily Market Reports | Oct 04 2022
This story features PENTANET LIMITED, and other companies. For more info SHARE ANALYSIS: 5GG
An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
5GG ADH AIM ALL ANZ (2) APC ART BEN (2) BOE BOQ BSL BXB CBA (2) CGC CGS CU6 DRO FSF GTK HLS IDX IRE MTO NAB (2) NST OZL PMV PWH SHL SIG STO STX TLX (2) TPW UNI WBC (2)
5GG PENTANET LIMITED
Telecommunication – Overnight Price: $0.28
Bell Potter rates ((5GG)) as Buy (1) –
New pricing tiers launched by Pentanet for its NVIDIA's GeForce NOW cloud gaming service represent a transition into a monetisation phase for the company, according to Bell Potter.
The broker highlights four price tiers, compared to the previous two improves accessibility of the service to customers unable or unwilling to pay for the premium tier.
The Buy rating is retained and the target price decreases to $0.48 from $0.56.
This report was published on September 29, 2022.
Target price is $0.48 Current Price is $0.28 Difference: $0.2
If 5GG meets the Bell Potter target it will return approximately 71% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 3.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 9.33.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 1.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 18.67.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ADH ADAIRS LIMITED
Furniture & Renovation – Overnight Price: $1.79
Jarden rates ((ADH)) as Overweight (2) –
Jarden feels Adairs' omnichannel mix provides a hedge against a shift in consumer traffic and purchasing behaviour across channels and retains its Overweight rating.
The weaker consumer backdrop and supply chain disruption are allowed for in the current share price, according to the broker.
Should physical retail sales continue to recover as per recent data, and/or if freight rates continue to normalise, the analyst sees upside earnings risk. It's also thought greater visibility on discretionary consumer spending may provide a boost.
The target price slips to $3.22 from $3.28.
This report was published on September 27, 2022.
Target price is $3.22 Current Price is $1.79 Difference: $1.43
If ADH meets the Jarden target it will return approximately 80% (excluding dividends, fees and charges).
Current consensus price target is $2.73, suggesting upside of 43.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 20.00 cents and EPS of 30.00 cents.
At the last closing share price the estimated dividend yield is 11.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.97.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 29.3, implying annual growth of 11.1%.
Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 9.9%.
Current consensus EPS estimate suggests the PER is 6.5.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 23.00 cents and EPS of 34.40 cents.
At the last closing share price the estimated dividend yield is 12.85%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.20.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 33.5, implying annual growth of 14.3%.
Current consensus DPS estimate is 22.0, implying a prospective dividend yield of 11.5%.
Current consensus EPS estimate suggests the PER is 5.7.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AIM AI-MEDIA TECHNOLOGIES LIMITED
Commercial Services & Supplies – Overnight Price: $0.36
Bell Potter rates ((AIM)) as Buy (1) –
Ai-Media Technologies has successfully renewed its exclusive agreement with the Seven Network for an additional five years. Bell Potter reports the renewal will extend Seven Network's use of Ai-Media Technologies's offerings.
As per the agreement, Seven Network will also purchase iCap Encode hardware at a cost of US$10,000 per encoder, and pay monthly captioning and equipment support fees. Bell Potter notes the agreement provides a recurring revenue stream for Ai-Media Technologies.
The Buy rating and target price of $0.70 are retained.
This report was published on September 30, 2022.
Target price is $0.70 Current Price is $0.36 Difference: $0.34
If AIM meets the Bell Potter target it will return approximately 94% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 0.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 72.00.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 45.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ALL ARISTOCRAT LEISURE LIMITED
Gaming – Overnight Price: $32.18
Goldman Sachs rates ((ALL)) as Buy (1) –
Goldman Sachs makes no material change to its forecasts for Aristocrat Leisure, following an investor day.
The broker notes some weakness in A&NZ operations due to weather and supply chain issues, though management stated customers have been well informed and none have been lost.
FY22 guidance was maintained in line with the outlook statement after 1H results.
Goldman Sachs retains its Buy rating and $43.00 target price.
This report was published on September 28, 2022.
Target price is $43.00 Current Price is $32.18 Difference: $10.82
If ALL meets the Goldman Sachs target it will return approximately 34% (excluding dividends, fees and charges).
Current consensus price target is $42.71, suggesting upside of 31.4%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Goldman Sachs forecasts a full year FY22 dividend of 63.00 cents and EPS of 176.00 cents.
At the last closing share price the estimated dividend yield is 1.96%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.28.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 163.1, implying annual growth of 27.3%.
Current consensus DPS estimate is 58.4, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 19.9.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 dividend of 76.00 cents and EPS of 191.00 cents.
At the last closing share price the estimated dividend yield is 2.36%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.85.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 184.2, implying annual growth of 12.9%.
Current consensus DPS estimate is 69.8, implying a prospective dividend yield of 2.1%.
Current consensus EPS estimate suggests the PER is 17.6.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ANZ AUSTRALIA AND NEW ZEALAND BANKING GROUP LIMITED
Banks – Overnight Price: $22.77
Goldman Sachs rates ((ANZ)) as Neutral (3) –
Goldman Sachs believes value exists in the Australian Bank sector and raises its 12-month target prices by 1-2% across the board.
The broker believes profitability can be boosted by rate rises (particularly in the form of lower funding costs, albeit somewhat offset by higher costs), and increases its sector net interest margin (NIM) assumptions for FY24.
Goldman Sachs lifts its target price for ANZ Bank to $26.36 from $25.89 and retains its Neutral rating.
This report was published on September 28, 2022.
Target price is $26.36 Current Price is $22.77 Difference: $3.59
If ANZ meets the Goldman Sachs target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $26.58, suggesting upside of 13.1%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Goldman Sachs forecasts a full year FY22 dividend of 144.00 cents and EPS of 214.00 cents.
At the last closing share price the estimated dividend yield is 6.32%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.64.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 211.3, implying annual growth of -1.9%.
Current consensus DPS estimate is 141.8, implying a prospective dividend yield of 6.0%.
Current consensus EPS estimate suggests the PER is 11.1.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 dividend of 150.00 cents and EPS of 215.00 cents.
At the last closing share price the estimated dividend yield is 6.59%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.59.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 219.3, implying annual growth of 3.8%.
Current consensus DPS estimate is 149.0, implying a prospective dividend yield of 6.3%.
Current consensus EPS estimate suggests the PER is 10.7.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((ANZ)) as Underweight (4) –
Jarden increases target prices slightly for the four major Australian banks to reflect the potential for stronger near-term margin expansion, as deposit pricing remains benign. Modestly lower credit growth forecasts provide a partial offset to EPS upgrades.
However, the broker feels this is "as good as it gets" for the banks, with FY24 earnings forecasts impacted by increased competition for mortgages and deposits, along with an increased level of provisioning.
Jarden maintains its Underweight rating for ANZ Bank and increases its target to $23.50 from $23.00.
This report was published on September 27, 2022.
Target price is $23.50 Current Price is $22.77 Difference: $0.73
If ANZ meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $26.58, suggesting upside of 13.1%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 145.00 cents and EPS of 226.00 cents.
At the last closing share price the estimated dividend yield is 6.37%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 211.3, implying annual growth of -1.9%.
Current consensus DPS estimate is 141.8, implying a prospective dividend yield of 6.0%.
Current consensus EPS estimate suggests the PER is 11.1.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 146.00 cents and EPS of 230.00 cents.
At the last closing share price the estimated dividend yield is 6.41%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.90.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 219.3, implying annual growth of 3.8%.
Current consensus DPS estimate is 149.0, implying a prospective dividend yield of 6.3%.
Current consensus EPS estimate suggests the PER is 10.7.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
APC AUSTRALIAN POTASH LIMITED
Agriculture – Overnight Price: $0.03
Shaw and Partners rates ((APC)) as Buy (1) –
Australian Potash has released updated operational and financial parameters for its Lake Wells sulphate of potash project, increasing production to 205,000 tonnes per annum from 170,000 tonnes per annum.
Operational expenditure has lifted to -US$295 per tonne from -US$251 per tonne, and capital expenditure to -$408m from -$292m.
Having already assumed higher sulphate of potash prices, Shaw and Partners more conservative valuation declines to $256m from $305m accounting for the update.
The Buy rating is retained and the target price decreases to $0.16 from $0.21.
This report was published on September 27, 2022.
Target price is $0.16 Current Price is $0.03 Difference: $0.13
If APC meets the Shaw and Partners target it will return approximately 433% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY22:
Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 0.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 6.00.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 0.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 6.00.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ART AIRTASKER LIMITED
Online media & mobile platforms – Overnight Price: $0.31
Shaw and Partners rates ((ART)) as Initiation of coverage with Buy (1) –
Shaw and Partners initiates coverage on Airtasker, an online marketplace with a platform that facilitates introductions and transactions between customers requiring a service and independent contractors.
Having been focused on scaling up its domestic platform and continuing to attract customers over the last decade, Airtasker will look to replicate its strategy offshore.The company has entered new markets including the UK in FY18 and the US in FY21.
Shaw and Partners considers the company to be at an inflection point in terms of scale, expansion and earnings. The broker initiates with a Buy rating and a target price of $0.50.
This report was published on September 30, 2022.
Target price is $0.50 Current Price is $0.31 Difference: $0.19
If ART meets the Shaw and Partners target it will return approximately 61% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 3.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 9.69.
Forecast for FY24:
Shaw and Partners forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 1.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.22.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BEN BENDIGO & ADELAIDE BANK LIMITED
Banks – Overnight Price: $7.85
Goldman Sachs rates ((BEN)) as Neutral (3) –
Goldman Sachs believes value exists in the Australian Bank sector and raises its 12-month target prices by 1-2% across the board.
The broker believes profitability can be boosted by rate rises (particularly in the form of lower funding costs, albeit somewhat offset by higher costs), and increases its sector net interest margin (NIM) assumptions for FY24.
For Bendigo & Adelaide Bank, Goldman Sachs lifts its target price to $11.06 from $10.50 and retains its Neutral rating.
This report was published on September 28, 2022.
Target price is $11.06 Current Price is $7.85 Difference: $3.21
If BEN meets the Goldman Sachs target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $9.83, suggesting upside of 23.3%(ex-dividends)
Forecast for FY23:
Current consensus EPS estimate is 77.8, implying annual growth of -11.1%.
Current consensus DPS estimate is 54.6, implying a prospective dividend yield of 6.9%.
Current consensus EPS estimate suggests the PER is 10.2.
Forecast for FY24:
Current consensus EPS estimate is 77.0, implying annual growth of -1.0%.
Current consensus DPS estimate is 56.2, implying a prospective dividend yield of 7.1%.
Current consensus EPS estimate suggests the PER is 10.4.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((BEN)) as Upgrade to Neutral from Underweight (3) –
Jarden increases target prices slightly across the board for the four major Australian banks to reflect the potential for stronger near-term margin expansion, as deposit pricing remains benign. Modestly lower credit growth forecasts provide a partial offset to EPS upgrades.
However, the broker feels this is "as good as it gets" for the banks, with FY24 earnings forecasts impacted by increased competition for mortgages and deposits, along with an increased level of provisioning.
Given recent share price weakness, Jarden lifts its rating for Bendigo & Adelaide Bank to Neutral from Underperform. In contrast to targets for the four major banks, the target is lowered to $9.00 from $9.30 on small compositional earnings changes.
This report was published on September 27, 2022.
Target price is $9.00 Current Price is $7.85 Difference: $1.15
If BEN meets the Jarden target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $9.83, suggesting upside of 23.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 54.00 cents and EPS of 76.00 cents.
At the last closing share price the estimated dividend yield is 6.88%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 77.8, implying annual growth of -11.1%.
Current consensus DPS estimate is 54.6, implying a prospective dividend yield of 6.9%.
Current consensus EPS estimate suggests the PER is 10.2.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 55.00 cents and EPS of 77.00 cents.
At the last closing share price the estimated dividend yield is 7.01%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.19.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 77.0, implying annual growth of -1.0%.
Current consensus DPS estimate is 56.2, implying a prospective dividend yield of 7.1%.
Current consensus EPS estimate suggests the PER is 10.4.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BOE BOSS ENERGY LIMITED
Uranium – Overnight Price: $2.51
Bell Potter rates ((BOE)) as Buy (1) –
An update from Boss Energy on its Honeymoon asset has the project on budget and on time, with Bell Potter reporting the company is progressing to schedule first production in the December quarter of 2023.
The broker warns recent inflationary pressure may impact as construction activity picks up in coming weeks.
The company also delivered a better than expected full year result at the net profit line, with a loss of -$6.1m a notable beat to the broker's expected -$11.5m. The broker attributed the miss to treatment of finance expenses.
The Buy rating is retained and the target price increases to $3.51 from $3.32.
This report was published on September 30, 2022.
Target price is $3.51 Current Price is $2.51 Difference: $1
If BOE meets the Bell Potter target it will return approximately 40% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 2.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 114.09.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 8.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.99.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BOQ BANK OF QUEENSLAND LIMITED
Banks – Overnight Price: $6.57
Goldman Sachs rates ((BOQ)) as Neutral (3) –
Goldman Sachs believes value exists in the Australian Bank sector and raises its 12-month target prices by 1-2% across the board.
The broker believes profitability can be boosted by rate rises (particularly in the form of lower funding costs, albeit somewhat offset by higher costs), and increases its sector net interest margin (NIM) assumptions for FY24.
For Bank of Queensland, Goldman Sachs sets its target price at $9.01 and retains its Neutral rating.
This report was published on September 28, 2022.
Target price is $9.01 Current Price is $6.57 Difference: $2.44
If BOQ meets the Goldman Sachs target it will return approximately 37% (excluding dividends, fees and charges).
Current consensus price target is $8.66, suggesting upside of 27.6%(ex-dividends)
Forecast for FY22:
Current consensus EPS estimate is 72.5, implying annual growth of 8.3%.
Current consensus DPS estimate is 45.8, implying a prospective dividend yield of 6.7%.
Current consensus EPS estimate suggests the PER is 9.4.
Forecast for FY23:
Current consensus EPS estimate is 72.1, implying annual growth of -0.6%.
Current consensus DPS estimate is 49.2, implying a prospective dividend yield of 7.2%.
Current consensus EPS estimate suggests the PER is 9.4.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BSL BLUESCOPE STEEL LIMITED
Steel & Scrap – Overnight Price: $15.39
Jarden rates ((BSL)) as Overweight (2) –
After reviewing US and Asian steel spreads, Jarden believes 1H FY23 earnings (EBIT) for BlueScope Steel are tracking at the mid- to high end of the guidance range of $800-900m.
The analyst observed a lot of ESG focus from investors at the company's investor day. It's thought BlueScope is constrained by the technology available to use alternative energy sources in the production process, especially hydrogen.
A Federal government white paper in December should provide more certainty on the emission reduction target for the Australian steel industry, notes the broker.
The Overweight rating and $20.80 target price are retained.
This report was published on September 23, 2022.
Target price is $20.80 Current Price is $15.39 Difference: $5.41
If BSL meets the Jarden target it will return approximately 35% (excluding dividends, fees and charges).
Current consensus price target is $20.83, suggesting upside of 31.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 50.00 cents and EPS of 296.80 cents.
At the last closing share price the estimated dividend yield is 3.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.19.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 251.2, implying annual growth of -56.0%.
Current consensus DPS estimate is 50.0, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 6.3.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 50.00 cents and EPS of 168.90 cents.
At the last closing share price the estimated dividend yield is 3.25%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.11.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 192.6, implying annual growth of -23.3%.
Current consensus DPS estimate is 50.0, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 8.2.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BXB BRAMBLES LIMITED
Transportation & Logistics – Overnight Price: $11.23
Jarden rates ((BXB)) as Overweight (2) –
In a recent assessment of the US market, Jarden finds the pallet pricing environment remains supportive for Brambles.
The first half of FY23 has seen transport costs increase 8.9% and lumber costs 3.3%, but pallet industry pricing strategies have proven effective at keeping wooden pallet prices elevated.
The broker finds Brambles well placed to sustain cost inflation into FY23, and sees potential in lower lumber and transport costs to benefit profit margins.
The Overweight rating and target price of $12.60 are retained.
This report was published on September 30, 2022.
Target price is $12.60 Current Price is $11.23 Difference: $1.37
If BXB meets the Jarden target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $13.24, suggesting upside of 15.5%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 43.93 cents and EPS of 63.44 cents.
At the last closing share price the estimated dividend yield is 3.91%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.70.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 73.7, implying annual growth of N/A.
Current consensus DPS estimate is 37.9, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 15.5.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 46.60 cents and EPS of 67.37 cents.
At the last closing share price the estimated dividend yield is 4.15%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 79.9, implying annual growth of 8.4%.
Current consensus DPS estimate is 41.5, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 14.3.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CBA COMMONWEALTH BANK OF AUSTRALIA
Banks – Overnight Price: $90.61
Goldman Sachs rates ((CBA)) as Sell (5) –
Goldman Sachs believes value exists in the Australian Bank sector and raises its 12-month target prices by 1-2% across the board.
The broker believes profitability can be boosted by rate rises (particularly in the form of lower funding costs, albeit somewhat offset by higher costs), and increases its sector net interest margin (NIM) assumptions in FY24.
Goldman Sachs lifts its target price for CommBank to $87.85 from $86.86 and retains its Sell rating.
This report was published on September 28, 2022.
Target price is $87.85 Current Price is $90.61 Difference: minus $2.76 (current price is over target).
If CBA meets the Goldman Sachs target it will return approximately minus 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $89.83, suggesting downside of -3.4%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 dividend of 439.00 cents and EPS of 560.00 cents.
At the last closing share price the estimated dividend yield is 4.84%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 571.1, implying annual growth of -8.7%.
Current consensus DPS estimate is 419.8, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.3.
Forecast for FY24:
Goldman Sachs forecasts a full year FY24 dividend of 466.00 cents and EPS of 584.00 cents.
At the last closing share price the estimated dividend yield is 5.14%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.52.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 583.0, implying annual growth of 2.1%.
Current consensus DPS estimate is 439.2, implying a prospective dividend yield of 4.7%.
Current consensus EPS estimate suggests the PER is 15.9.
Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((CBA)) as Neutral (3) –
Jarden increases target prices slightly for the four major Australian banks to reflect the potential for stronger near-term margin expansion, as deposit pricing remains benign. Modestly lower credit growth forecasts provide a partial offset to EPS upgrades.
However, the broker feels this is "as good as it gets" for the banks, with FY24 earnings forecasts impacted by increased competition for mortgages and deposits, along with an increased level of provisioning.
Jarden maintains its Neutral rating for CommBank and increases its target to $101 from $100.
This report was published on September 27, 2022.
Target price is $101.00 Current Price is $90.61 Difference: $10.39
If CBA meets the Jarden target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $89.83, suggesting downside of -3.4%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 419.00 cents and EPS of 555.00 cents.
At the last closing share price the estimated dividend yield is 4.62%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 571.1, implying annual growth of -8.7%.
Current consensus DPS estimate is 419.8, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.3.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 422.00 cents and EPS of 556.00 cents.
At the last closing share price the estimated dividend yield is 4.66%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.30.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 583.0, implying annual growth of 2.1%.
Current consensus DPS estimate is 439.2, implying a prospective dividend yield of 4.7%.
Current consensus EPS estimate suggests the PER is 15.9.
Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CGC COSTA GROUP HOLDINGS LIMITED
Agriculture – Overnight Price: $2.17
Jarden rates ((CGC)) as Overweight (2) –
Jarden leaves its forecasts unchanged and feels Costa Group is executing well in what it can control.
One of the uncontrollables appears to be the sudden resignation of CEO Sean Hallahan, which came as a surprise to the analyst.
The Overweight rating and $3.15 target are retained and the broker notes interim CEO Harry Debney is well regarded.
This report was published on September 27, 2022.
Target price is $3.15 Current Price is $2.17 Difference: $0.98
If CGC meets the Jarden target it will return approximately 45% (excluding dividends, fees and charges).
Current consensus price target is $3.07, suggesting upside of 40.3%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 10.60 cents and EPS of 14.40 cents.
At the last closing share price the estimated dividend yield is 4.88%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.07.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.1, implying annual growth of 38.3%.
Current consensus DPS estimate is 8.8, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 16.7.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 10.80 cents and EPS of 17.90 cents.
At the last closing share price the estimated dividend yield is 4.98%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.12.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 18.4, implying annual growth of 40.5%.
Current consensus DPS estimate is 11.3, implying a prospective dividend yield of 5.2%.
Current consensus EPS estimate suggests the PER is 11.9.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CGS COGSTATE LIMITED
Medical Equipment & Devices – Overnight Price: $2.14
Bell Potter rates ((CGS)) as Buy (1) –
Positive results from Cogstate's contract partner Eisai's lecanemab treatment should prove positive for Cogstate, which will benefit from sustained drug development interest.
Bell Potter notes in its Phase 3 study lecanemab demonstrated a reduced decline in cognition and function of 27% compared to placebo treatments. Full data are expected to be published in November.
The Buy rating is retained and the target price increases to $2.20 from $1.95.
This report was published on September 30, 2022.
Target price is $2.20 Current Price is $2.14 Difference: $0.06
If CGS meets the Bell Potter target it will return approximately 3% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of 4.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 48.64.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 5.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.63.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CU6 CLARITY PHARMACEUTICALS LIMITED
Medical Equipment & Devices – Overnight Price: $0.64
Bell Potter rates ((CU6)) as Buy (1) –
Bell Potter suggests Clarity Pharmaceuticals's imaging trial for men with previously untreated prostate cancer considered at high risk of metatastic disease will be addressing a high unmet need, with conventional imaging techniques not effective with early stage diagnosis.
A data release from the trial is upcoming to provide further detail around the diagnostic capabilities of Clarity Pharmaceuticals' CuSAR-bisPSMA treatment.
The broker expects successful development of an early diagnosing radiopharmaceutical to be highly differentiated from current market offerings.
The Buy rating and target price of $1.00 are retained.
This report was published on September 27, 2022.
Target price is $1.00 Current Price is $0.64 Difference: $0.36
If CU6 meets the Bell Potter target it will return approximately 56% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 14.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 4.44.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 18.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 3.40.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
DRO DRONESHIELD LIMITED
Hardware & Equipment – Overnight Price: $0.16
Bell Potter rates ((DRO)) as Initiation of coverage with Buy (1) –
Bell Potter initiates coverage on DroneShield, a domestic defense manufacturer specialising in counter-drone technology with a range of products used to detect and defeat aerial, ground and maritime threats.
The broker has identified opportunity for DroneShield to utilise its in-house technology to expand into the electronic welfare market.
Bell Potter finds DroneShield well place to capitalise on macroeconomic conditions, and likes that the company's strong sales pipeline demonstrates long-term demand.
The broker initiates with a Buy rating and a target price of $0.24.
This report was published on September 27, 2022.
Target price is $0.24 Current Price is $0.16 Difference: $0.08
If DRO meets the Bell Potter target it will return approximately 50% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY22:
Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 0.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.78.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of 0.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 160.00.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FSF FONTERRA SHAREHOLDERS FUND
Dairy – Overnight Price: $2.68
Jarden rates ((FSF)) as Overweight (2) –
FY22 results for Fonterra Shareholders Fund and a NZ20cps FY22 dividend were in line with Jarden's forecasts.
A strong end of financial year performance helps support the broker's FY23 EPS estimate, and the Overweight rating is maintained.
Following a strategic review, Fonterra has decided not to proceed with a partial exit of Australia, with the country set to “play a key role in helping us get to our 2030 strategic targets”.
The analyst is disappointed by a lack of rationale provided for this decision. The target rises to NZ$3.81 from NZ$3.76.
This report was published on September 23, 2022.
Current Price is $2.68. Target price not assessed.
The company's fiscal year ends in July.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 27.69 cents and EPS of 50.48 cents.
At the last closing share price the estimated dividend yield is 10.33%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.31.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 25.38 cents and EPS of 38.85 cents.
At the last closing share price the estimated dividend yield is 9.47%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.90.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GTK GENTRACK GROUP LIMITED
Software & Services – Overnight Price: $1.31
Shaw and Partners rates ((GTK)) as Buy (1) –
Gentrack Group looks to deliver an impressive end to the year according to Shaw and Partners, with the company upgrading full year revenue guidance to $125m from $115m despite key market volatility.
The broker finds Gentrack Group's well-progressed turnaround not reflected in the share price, with the stock one of the cheapest in Shaw and Partners' software coverage despite clear growth, wins, and significant operating leverage beyond the company's FY24 targets.
The Buy rating and target price of $2.90 are retained.
This report was published on September 30, 2022.
Target price is $2.90 Current Price is $1.31 Difference: $1.59
If GTK meets the Shaw and Partners target it will return approximately 121% (excluding dividends, fees and charges).
The company's fiscal year ends in September.
Forecast for FY22:
Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 2.68 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 48.95.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HLS HEALIUS LIMITED
Healthcare services – Overnight Price: $3.32
Jarden rates ((HLS)) as Neutral (3) –
August Medicare data show growth for Diagnostic Imaging (across Australia) and Pathology base business segments tracked ahead of Jarden's expectations.
As a result, the analysts upgrade Healius' Australian Pathology and Imaging base business growth. Forecasts also allow for cuts to PCR testing revenues in FY23, with a -19% reimbursement cut in Australia being issued three months earlier than expected.
The Neutral rating is retained due to the variable nature of monthly Medicare data and a backdrop of potential further PCR reimbursement cuts. The target rises to $3.61 from $3.50.
This report was published on September 28, 2022.
Target price is $3.61 Current Price is $3.32 Difference: $0.29
If HLS meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $4.14, suggesting upside of 23.3%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 12.40 cents and EPS of 21.80 cents.
At the last closing share price the estimated dividend yield is 3.73%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.23.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 19.6, implying annual growth of -60.8%.
Current consensus DPS estimate is 11.9, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 17.1.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 13.10 cents and EPS of 22.60 cents.
At the last closing share price the estimated dividend yield is 3.95%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.69.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.6, implying annual growth of 15.3%.
Current consensus DPS estimate is 13.6, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 14.9.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IDX INTEGRAL DIAGNOSTICS LIMITED
Medical Equipment & Devices – Overnight Price: $2.72
Jarden rates ((IDX)) as Overweight (2) –
August Medicare data show growth for Diagnostic Imaging (across Australia) and Pathology base business segments tracked ahead of Jarden's expectations.
The analysts keep the Overweight rating for Integral Diagnostics and continue to expect weak Diagnostic Imaging volumes in Australia to be transitory. Eventually volumes should rebound due to a growing elective surgery backlog. The $3.89 target is unchanged.
This report was published on September 28, 2022.
Target price is $3.89 Current Price is $2.72 Difference: $1.17
If IDX meets the Jarden target it will return approximately 43% (excluding dividends, fees and charges).
Current consensus price target is $3.09, suggesting upside of 15.1%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 5.80 cents and EPS of 13.50 cents.
At the last closing share price the estimated dividend yield is 2.13%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.15.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.6, implying annual growth of 94.8%.
Current consensus DPS estimate is 8.9, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 19.7.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 8.10 cents and EPS of 18.40 cents.
At the last closing share price the estimated dividend yield is 2.98%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.78.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.1, implying annual growth of 25.7%.
Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 15.7.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IRE IRESS LIMITED
Wealth Management & Investments – Overnight Price: $8.92
Shaw and Partners rates ((IRE)) as Upgrade to Hold from Sell (3) –
Iress has announced what Shaw and Partners described as an unexpected contract win with the Commonwealth Superannuation Corporation (CSC). The agreement will see CSC adopt Iress' Acurity administration software.
Less positively, the company also announced another downgrade to FY22 segment profit guidance, now $166-170m compared to the previous $177-183m. Delays on converting new sales and higher than anticipated technology supplier costs were key drivers.
The rating is upgraded to Hold from Sell and the target price decreases to $11.60 from $11.90.
This report was published on September 30, 2022.
Target price is $11.60 Current Price is $8.92 Difference: $2.68
If IRE meets the Shaw and Partners target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $11.78, suggesting upside of 28.9%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY22:
Shaw and Partners forecasts a full year FY22 dividend of 46.00 cents and EPS of 43.10 cents.
At the last closing share price the estimated dividend yield is 5.16%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.70.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 38.7, implying annual growth of -0.2%.
Current consensus DPS estimate is 46.0, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 23.6.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 46.00 cents and EPS of 45.50 cents.
At the last closing share price the estimated dividend yield is 5.16%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.60.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 44.0, implying annual growth of 13.7%.
Current consensus DPS estimate is 47.0, implying a prospective dividend yield of 5.1%.
Current consensus EPS estimate suggests the PER is 20.8.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MTO MOTORCYCLE HOLDINGS LIMITED
Automobiles & Components – Overnight Price: $2.57
Moelis rates ((MTO)) as Buy (1) –
Motorcycle Holdings will acquire Mojo Group for -$60m. Mojo Group, which imports and distributes six brands of motorcycles, scooters, ATVS, electronic motorcycles and parts and accessories, has delivered strong growth in the last two years.
Moelis expects the acquisition to be 18% earnings per share accretive on a pro-forma basis, and notes while current buoyant market conditions will unwind at some point, it finds this already reflected in the purchase price.
The broker finds the purchase sensible, noting it will add diversification. The Buy rating is retained and the target price increases to $3.08 from $2.50.
This report was published on September 27, 2022.
Target price is $3.08 Current Price is $2.57 Difference: $0.51
If MTO meets the Moelis target it will return approximately 20% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Moelis forecasts a full year FY23 dividend of 21.00 cents and EPS of 34.50 cents.
At the last closing share price the estimated dividend yield is 8.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.45.
Forecast for FY24:
Moelis forecasts a full year FY24 dividend of 17.20 cents and EPS of 28.60 cents.
At the last closing share price the estimated dividend yield is 6.69%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.99.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NAB NATIONAL AUSTRALIA BANK LIMITED
Banks – Overnight Price: $28.73
Goldman Sachs rates ((NAB)) as Buy (1) –
Goldman Sachs believes value exists in the Australian Bank sector and raises its 12-month target prices by 1-2% across the board.
The broker believes profitability can be boosted by rate rises (particularly in the form of lower funding costs, albeit somewhat offset by higher costs), and increases its sector net interest margin (NIM) assumptions for FY24.
Goldman Sachs lifts its target price for National Australia Bank to $35.15 from $34.63 and retains its Buy rating.
This report was published on September 28, 2022.
Target price is $35.15 Current Price is $28.73 Difference: $6.42
If NAB meets the Goldman Sachs target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $31.76, suggesting upside of 7.4%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Goldman Sachs forecasts a full year FY22 dividend of 151.00 cents and EPS of 214.00 cents.
At the last closing share price the estimated dividend yield is 5.26%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.43.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 211.6, implying annual growth of 9.6%.
Current consensus DPS estimate is 149.0, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 14.0.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 dividend of 168.00 cents and EPS of 238.00 cents.
At the last closing share price the estimated dividend yield is 5.85%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.07.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 236.4, implying annual growth of 11.7%.
Current consensus DPS estimate is 165.8, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 12.5.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((NAB)) as Overweight (2) –
Jarden increases target prices slightly for the four major Australian banks to reflect the potential for stronger near-term margin expansion, as deposit pricing remains benign. Modestly lower credit growth forecasts provide a partial offset to EPS upgrades.
However, the broker feels this is "as good as it gets" for the banks, with FY24 earnings forecasts impacted by increased competition for mortgages and deposits, along with an increased level of provisioning.
Jarden's preferred exposure is National Australia Bank and an Overweight rating is maintained. The target is increased to $32 from $31.
This report was published on September 27, 2022.
Target price is $32.00 Current Price is $28.73 Difference: $3.27
If NAB meets the Jarden target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $31.76, suggesting upside of 7.4%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 149.00 cents and EPS of 211.00 cents.
At the last closing share price the estimated dividend yield is 5.19%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.62.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 211.6, implying annual growth of 9.6%.
Current consensus DPS estimate is 149.0, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 14.0.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 159.00 cents and EPS of 234.00 cents.
At the last closing share price the estimated dividend yield is 5.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.28.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 236.4, implying annual growth of 11.7%.
Current consensus DPS estimate is 165.8, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 12.5.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NST NORTHERN STAR RESOURCES LIMITED
Gold & Silver – Overnight Price: $7.67
JP Morgan rates ((NST)) as Overweight (1) –
The Pogo gold operations in Alaska currently represent 15% of JP Morgan's total valuation for Northern Star Resources.
The broker recently visited the site and is now more positive around management's targets for 300kozpa and an under $1,000/oz all-in sustaining cost (AISC). A target for a 10 year reserve is also considered to be achievable.
The company remains JP Morgan's key Gold sector pick and the Overweight rating and $9.25 target price are maintained.
This report was published on September 27, 2022.
Target price is $9.25 Current Price is $7.67 Difference: $1.58
If NST meets the JP Morgan target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $10.03, suggesting upside of 22.4%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
JP Morgan forecasts a full year FY23 dividend of 25.00 cents and EPS of 36.00 cents.
At the last closing share price the estimated dividend yield is 3.26%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.31.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 29.9, implying annual growth of -19.1%.
Current consensus DPS estimate is 22.6, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 27.4.
Forecast for FY24:
JP Morgan forecasts a full year FY24 dividend of 31.00 cents and EPS of 56.00 cents.
At the last closing share price the estimated dividend yield is 4.04%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.70.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 37.8, implying annual growth of 26.4%.
Current consensus DPS estimate is 25.1, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 21.7.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
OZL OZ MINERALS LIMITED
Copper – Overnight Price: $25.80
Shaw and Partners rates ((OZL)) as Buy (1) –
As Shaw and Partners had anticipated, OZ Minerals will proceed with its West Musgrave project following the delivery of a favourable final investment decision.
The company has guided to a capital investment of -$1.7bn, with key banks to provide a new $1.2bn loan facility on an 18-month term. It is Shaw and Partners' view that West Musgrave will take OZ Minerals to the next production, earnings and valuation level.
The Buy rating and target price of $30.00 are retained.
This report was published on September 27, 2022.
Target price is $30.00 Current Price is $25.80 Difference: $4.2
If OZL meets the Shaw and Partners target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $25.48, suggesting downside of -3.8%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY22:
Shaw and Partners forecasts a full year FY22 dividend of 26.00 cents and EPS of 82.00 cents.
At the last closing share price the estimated dividend yield is 1.01%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 31.46.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 80.3, implying annual growth of -49.7%.
Current consensus DPS estimate is 17.5, implying a prospective dividend yield of 0.7%.
Current consensus EPS estimate suggests the PER is 33.0.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 28.00 cents and EPS of 121.90 cents.
At the last closing share price the estimated dividend yield is 1.09%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.16.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 98.5, implying annual growth of 22.7%.
Current consensus DPS estimate is 15.2, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 26.9.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PMV PREMIER INVESTMENTS LIMITED
Apparel & Footwear – Overnight Price: $22.43
Shaw and Partners rates ((PMV)) as Buy (1) –
A prioritisation of profitable growth and strong margin control has seen Premier Investments deliver full year results ahead of market. Shaw and Partners highlights retail earnings were up 10% year-on-year and revenues 4% year-on-year.
The company has also reported a strong start to the new financial year, with the first seven weeks of trading up 47% year-on-year and 22% on pre-covid. Shaw and Partners updates its sales forecasts 3.3%, 2.1% and -1.9% through to FY24.
The Buy rating is retained and the target price increases to $27.50 from $27.10.
This report was published on September 30, 2022.
Target price is $27.50 Current Price is $22.43 Difference: $5.07
If PMV meets the Shaw and Partners target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $25.61, suggesting upside of 9.3%(ex-dividends)
The company's fiscal year ends in July.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 77.00 cents and EPS of 154.10 cents.
At the last closing share price the estimated dividend yield is 3.43%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.56.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 139.3, implying annual growth of -22.4%.
Current consensus DPS estimate is 100.9, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 16.8.
Forecast for FY24:
Shaw and Partners forecasts a full year FY24 dividend of 76.00 cents and EPS of 152.10 cents.
At the last closing share price the estimated dividend yield is 3.39%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.75.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 142.5, implying annual growth of 2.3%.
Current consensus DPS estimate is 106.4, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.4.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PWH PWR HOLDINGS LIMITED
Automobiles & Components – Overnight Price: $8.47
Bell Potter rates ((PWH)) as Hold (3) –
With PWR Holdings having currency exposure to both the British pound and the US dollar, Bell Potter estimates the company could face a -$1.25m impact to its net profit in FY23 if exchange rates are retained for the remainder of the financial year.
This impact would be comprised of a $0.75m benefit from the US dollar exchange rate being maintained, but a -$2.0m loss from the British pound exchange rate. The total impact amounts to -5% of total estimated net profit, which Bell Potter found not overly material.
The Hold rating is retained and the target price decreases to $9.50 from $9.75.
This report was published on September 27, 2022.
Target price is $9.50 Current Price is $8.47 Difference: $1.03
If PWH meets the Bell Potter target it will return approximately 12% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 13.50 cents and EPS of 23.20 cents.
At the last closing share price the estimated dividend yield is 1.59%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 36.51.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 15.80 cents and EPS of 27.90 cents.
At the last closing share price the estimated dividend yield is 1.87%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.36.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SHL SONIC HEALTHCARE LIMITED
Healthcare services – Overnight Price: $30.50
Jarden rates ((SHL)) as Neutral (3) –
August Medicare data show growth for Diagnostic Imaging (across Australia) and Pathology base business segments tracked ahead of Jarden's expectations.
As a result, the analysts upgrade Sonic Healthcare's Australian Pathology and Imaging base business growth. Forecasts also allow for cuts to PCR testing revenues in FY23, with a -19% reimbursement cut in Australia being issued three months earlier than expected.
The Neutral rating is retained due to the variable nature of monthly Medicare data and a backdrop of potential further PCR reimbursement cuts. The target rises to $32.24 from $32.02.
This report was published on September 28, 2022.
Target price is $32.24 Current Price is $30.50 Difference: $1.74
If SHL meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $36.11, suggesting upside of 16.5%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 100.00 cents and EPS of 177.70 cents.
At the last closing share price the estimated dividend yield is 3.28%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.16.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 173.0, implying annual growth of -43.4%.
Current consensus DPS estimate is 102.8, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 17.9.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 100.00 cents and EPS of 158.90 cents.
At the last closing share price the estimated dividend yield is 3.28%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.19.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 151.7, implying annual growth of -12.3%.
Current consensus DPS estimate is 103.3, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 20.4.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SIG SIGMA HEALTHCARE LIMITED
Health & Nutrition – Overnight Price: $0.67
Shaw and Partners rates ((SIG)) as Downgrade to Hold from Buy (3) –
Shaw and Partners has found Sigma Healthcare's first half financial results encouraging, with both revenue and underlying earnings exceeding the broker's forecasts.
With its ERP implementation issues largely resolved, Sigma Healthcare's new Managing Director has outlined a strategy to create long-term value for shareholders through a diversified health, beauty and wellness offering.
Given recent share price strength, the rating is downgraded to Hold from Buy and the target price increases to $0.65 from $0.60.
This report was published on September 27, 2022.
Target price is $0.65 Current Price is $0.67 Difference: minus $0.02 (current price is over target).
If SIG meets the Shaw and Partners target it will return approximately minus 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $0.53, suggesting downside of -22.8%(ex-dividends)
The company's fiscal year ends in January.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 1.00 cents and EPS of 1.10 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 60.91.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 0.9, implying annual growth of N/A.
Current consensus DPS estimate is 1.1, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 75.6.
Forecast for FY24:
Shaw and Partners forecasts a full year FY24 dividend of 1.30 cents and EPS of 2.90 cents.
At the last closing share price the estimated dividend yield is 1.94%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 23.10.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 2.1, implying annual growth of 133.3%.
Current consensus DPS estimate is 1.6, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 32.4.
Market Sentiment: -0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
STO SANTOS LIMITED
NatGas – Overnight Price: $7.17
Jarden rates ((STO)) as Overweight (2) –
Jarden lowers its target price for Santos to $8.25 from $8.40 in reaction to the Barossa Drilling Environmental Plan being ruled invalid by Australia's Federal Court. Delays to the project are now expected and project cost forecasts are increased.
Risks have increased, assuming the decision isn't reversed on appeal, and the broker now switches its preference to Woodside Energy Group ((WDS)) in the sector.
The Overweight rating is maintained.
This report was published on September 23, 2022.
Target price is $8.25 Current Price is $7.17 Difference: $1.08
If STO meets the Jarden target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $9.46, suggesting upside of 27.4%(ex-dividends)
The company's fiscal year ends in December.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 39.44 cents and EPS of 101.33 cents.
At the last closing share price the estimated dividend yield is 5.50%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 136.4, implying annual growth of N/A.
Current consensus DPS estimate is 29.4, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 5.4.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 51.23 cents and EPS of 70.60 cents.
At the last closing share price the estimated dividend yield is 7.14%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.16.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 110.2, implying annual growth of -19.2%.
Current consensus DPS estimate is 40.2, implying a prospective dividend yield of 5.4%.
Current consensus EPS estimate suggests the PER is 6.7.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
STX STRIKE ENERGY LIMITED
NatGas – Overnight Price: $0.24
Bell Potter rates ((STX)) as Buy (1) –
Strike Energy has confirmed certified combined reserves and contingent resources of 306 petajoules at its South Erregulla project.
As Bell Potter highlights, with only the Kingia Sandstone contributing to the resource, testing at Wagina Sandstone should deliver upside.
The broker finds this to further de-risk Strike Energy's Project Haber, which is expected to require 80 terrajoules of natural gas per day. South Erregulla's 306 petajoules therefore amounts to ten years of urea production at Haber.
The Buy rating and target price of $0.42 are retained.
This report was published on September 29, 2022.
Target price is $0.42 Current Price is $0.24 Difference: $0.18
If STX meets the Bell Potter target it will return approximately 75% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY22:
Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 60.00.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of 0.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 60.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $4.76
Bell Potter rates ((TLX)) as Buy (1) –
Telix Pharmaceuticals has withdrawn its Illuccix application in Europe, following a request for additional data from the Danish Medicines Agency.
According to Bell Potter, the company is able to produce the additional chemistry, manufacturing and control data requested, but not in the given timeframe.
Withdrawal of the application allows Telix Pharmaceuticals to resubmit rather than receive a technical fail.
The broker anticipates approval can still be achieved in the fourth quarter of FY23. This pushes product launch from Bell Potter's expected mid-2023 to 2024.
The Buy rating is retained and the target price decreases to $8.50 from $8.65.
This report was published on September 29, 2022.
Target price is $8.50 Current Price is $4.76 Difference: $3.74
If TLX meets the Bell Potter target it will return approximately 79% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY22:
Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 23.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 20.43.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of 4.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 113.33.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((TLX)) as Buy (1) –
Telix Pharmaceuticals has withdrawn its Illucix marketing authorisation application in Europe, being unable to meet late requests for additional data. As Jarden highlights, issues with the application were with manufacturing, and not with clinical data.
The broker believes Telix Pharmaceuticals would have faced a technical objection had it not withdrawn. Withdrawal keeps several resubmission options open, and Jarden expects gaining regulatory approval in other jurisdictions to make resubmission easier.
The Buy rating is retained and the target price decreases to $6.80 from $6.89.
This report was published on September 28, 2022.
Target price is $6.80 Current Price is $4.76 Difference: $2.04
If TLX meets the Jarden target it will return approximately 43% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 29.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 15.97.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 8.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 54.71.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TPW TEMPLE & WEBSTER GROUP LIMITED
Furniture & Renovation – Overnight Price: $4.95
Jarden rates ((TPW)) as Downgrade to Neutral from Overweight (3) –
Jarden believes the consensus 1H FY23 sales forecast for Temple & Webster is too high, and sees revenue headwinds for pure online retailers. The broker lowers its rating to Neutral from Overweight.
Data (from Similarweb) show a significant fall in web traffic for Temple & Webster from mid-June, and an apparent -50% year-on-year
decline in traffic for the period from 17 August to 20 September 2022 is concerning to the analyst.
The broker lowers the 12-month target price to $5.42 from $6.49.
This report was published on September 27, 2022.
Target price is $5.42 Current Price is $4.95 Difference: $0.47
If TPW meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $6.09, suggesting upside of 18.6%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 0.00 cents and EPS of 8.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 58.24.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.8, implying annual growth of -21.5%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 65.8.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of 10.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 48.53.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 10.5, implying annual growth of 34.6%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 48.9.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UNI UNIVERSAL STORE HOLDINGS LIMITED
Apparel & Footwear – Overnight Price: $4.75
Jarden rates ((UNI)) as Buy (1) –
The -$50m purchase of vintage-inspired youth apparel designer, wholesaler and retailer Cheap Thrills Cycles is strategically sound, according to Jarden, and will expand Universal Store's own-brand portfolio. The analyst expects around 9% EPS accretion in FY23.
The broker raises its FY23-25 EPS estimates by 6-9% and the target price rises to $6.50 from $6.10. The Buy rating remains unchanged.
Jarden points out Universal Store is well positioned for a discretionary downturn partly because of youth fashion exposure and partly the store rollout opportunity.
This report was published on September 27, 2022.
Target price is $6.50 Current Price is $4.75 Difference: $1.75
If UNI meets the Jarden target it will return approximately 37% (excluding dividends, fees and charges).
Current consensus price target is $5.98, suggesting upside of 25.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 29.00 cents and EPS of 41.00 cents.
At the last closing share price the estimated dividend yield is 6.11%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.59.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 36.7, implying annual growth of 21.4%.
Current consensus DPS estimate is 25.3, implying a prospective dividend yield of 5.3%.
Current consensus EPS estimate suggests the PER is 13.0.
Forecast for FY24:
Jarden forecasts a full year FY24 dividend of 31.00 cents and EPS of 45.00 cents.
At the last closing share price the estimated dividend yield is 6.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.56.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 44.4, implying annual growth of 21.0%.
Current consensus DPS estimate is 27.4, implying a prospective dividend yield of 5.7%.
Current consensus EPS estimate suggests the PER is 10.8.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
WBC WESTPAC BANKING CORPORATION
Banks – Overnight Price: $20.60
Goldman Sachs rates ((WBC)) as Neutral (3) –
Goldman Sachs believes value exists in the Australian Bank sector and raises its 12-month target prices by 1-2% across the board.
The broker believes profitability can be boosted by rate rises (particularly in the form of lower funding costs, albeit somewhat offset by higher costs), and increases its sector net interest margin (NIM) assumptions for FY24.
Goldman Sachs lifts its target price for Westpac to $27.08 from $26.55 and retains its Neutral rating.
This report was published on September 28, 2022.
Target price is $27.08 Current Price is $20.60 Difference: $6.48
If WBC meets the Goldman Sachs target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $24.52, suggesting upside of 15.7%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Goldman Sachs forecasts a full year FY22 EPS of 140.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.71.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 144.2, implying annual growth of -3.5%.
Current consensus DPS estimate is 119.3, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 14.7.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 EPS of 190.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.84.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 194.8, implying annual growth of 35.1%.
Current consensus DPS estimate is 141.0, implying a prospective dividend yield of 6.7%.
Current consensus EPS estimate suggests the PER is 10.9.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Jarden rates ((WBC)) as Underweight (4) –
Jarden increases target prices slightly for the four major Australian banks to reflect the potential for stronger near-term margin expansion, as deposit pricing remains benign. Modestly lower credit growth forecasts provide a partial offset to EPS upgrades.
However, the broker feels this is "as good as it gets" for the banks, with FY24 earnings forecasts impacted by increased competition for mortgages and deposits, along with an increased level of provisioning.
Jarden maintains its Underweight rating for Westpac and increases its target to $22.60 from $22.50.
This report was published on September 27, 2022.
Target price is $22.60 Current Price is $20.60 Difference: $2
If WBC meets the Jarden target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $24.52, suggesting upside of 15.7%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 123.00 cents and EPS of 149.00 cents.
At the last closing share price the estimated dividend yield is 5.97%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.83.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 144.2, implying annual growth of -3.5%.
Current consensus DPS estimate is 119.3, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 14.7.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 127.00 cents and EPS of 193.00 cents.
At the last closing share price the estimated dividend yield is 6.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 194.8, implying annual growth of 35.1%.
Current consensus DPS estimate is 141.0, implying a prospective dividend yield of 6.7%.
Current consensus EPS estimate suggests the PER is 10.9.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface. This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
As part of emerging new trends overseas, The Australian Broker Call *Extra* Edition also includes providers of sponsored research. Readers should bear in mind, sponsored research, while not necessarily of lower quality, has the embedded complication that the company that is the subject of the research has paid for this research. Providers of sponsored research that can potentially be included in this Report are Breakaway Research, Edison Investment Research, Independent Investment Research, NDF Research, Pitt Street Research, and TMT Analytics.
Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: 5GG - PENTANET LIMITED
For more info SHARE ANALYSIS: ADH - ADAIRS LIMITED
For more info SHARE ANALYSIS: AIM - AI-MEDIA TECHNOLOGIES LIMITED
For more info SHARE ANALYSIS: ALL - ARISTOCRAT LEISURE LIMITED
For more info SHARE ANALYSIS: ANZ - ANZ GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: APC - APC MINERALS LIMITED
For more info SHARE ANALYSIS: ART - AIRTASKER LIMITED
For more info SHARE ANALYSIS: BEN - BENDIGO & ADELAIDE BANK LIMITED
For more info SHARE ANALYSIS: BOE - BOSS ENERGY LIMITED
For more info SHARE ANALYSIS: BOQ - BANK OF QUEENSLAND LIMITED
For more info SHARE ANALYSIS: BSL - BLUESCOPE STEEL LIMITED
For more info SHARE ANALYSIS: BXB - BRAMBLES LIMITED
For more info SHARE ANALYSIS: CBA - COMMONWEALTH BANK OF AUSTRALIA
For more info SHARE ANALYSIS: CGC - COSTA GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: CGS - COGSTATE LIMITED
For more info SHARE ANALYSIS: CU6 - CLARITY PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: DRO - DRONESHIELD LIMITED
For more info SHARE ANALYSIS: FSF - FONTERRA SHAREHOLDERS FUND
For more info SHARE ANALYSIS: GTK - GENTRACK GROUP LIMITED
For more info SHARE ANALYSIS: HLS - HEALIUS LIMITED
For more info SHARE ANALYSIS: IDX - INTEGRAL DIAGNOSTICS LIMITED
For more info SHARE ANALYSIS: IRE - IRESS LIMITED
For more info SHARE ANALYSIS: MTO - MOTORCYCLE HOLDINGS LIMITED
For more info SHARE ANALYSIS: NAB - NATIONAL AUSTRALIA BANK LIMITED
For more info SHARE ANALYSIS: NST - NORTHERN STAR RESOURCES LIMITED
For more info SHARE ANALYSIS: OZL - OZ MINERALS LIMITED
For more info SHARE ANALYSIS: PMV - PREMIER INVESTMENTS LIMITED
For more info SHARE ANALYSIS: PWH - PWR HOLDINGS LIMITED
For more info SHARE ANALYSIS: SHL - SONIC HEALTHCARE LIMITED
For more info SHARE ANALYSIS: SIG - SIGMA HEALTHCARE LIMITED
For more info SHARE ANALYSIS: STO - SANTOS LIMITED
For more info SHARE ANALYSIS: STX - STRIKE ENERGY LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: TPW - TEMPLE & WEBSTER GROUP LIMITED
For more info SHARE ANALYSIS: UNI - UNIVERSAL STORE HOLDINGS LIMITED
For more info SHARE ANALYSIS: WBC - WESTPAC BANKING CORPORATION
For more info SHARE ANALYSIS: WDS - WOODSIDE ENERGY GROUP LIMITED